Lin Xu

3.5k citations
65 papers · 2.3k indexed · 2 hit papers · h-index 23
Topics
Circular RNAs in diseases (8 papers)Cancer-related molecular mechanisms research (7 papers)RNA modifications and cancer (6 papers)
Journals
SHILAP Revista de lepidopterologíaPLoS ONECancer Research

In The Last Decade

Lin Xu

62 papers receiving 2.3k citations

Hit Papers

Signaling pathways and targeted therapy for myoca...201920262021202320222019100200300400500

Peers

Lin Xu
Comparison fields: 5 of 152
  • Molecular Biology 1.2k
  • Cancer Research 802
  • Oncology 345
  • Surgery 243
  • Cardiology and Cardiovascular Medicine 214
Replace Ning Zhang with:
Ning Zhang China
Zhigang Wang China
Zixian Wang China
Dan Wang China
Zeyu Wang China
Dehua Wu China
Lei Liang China
Liying Zhao China
Naoyoshi Onoda Japan
Emilio Alba Spain
Lin Xu relative to Ning Zhang China Ning Zhang's profile →
Citations per field
00.5×1.5×1.8×
Ning Zhang · 1×
Citations per year

Countries citing papers authored by Lin Xu

Since Specialization
Citations

This map shows the geographic impact of Lin Xu's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Lin Xu with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Lin Xu more than expected).

Fields of papers citing papers by Lin Xu

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Lin Xu. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Lin Xu. The network helps show where Lin Xu may publish in the future.

Co-authorship network of co-authors of Lin Xu

This figure shows the co-authorship network connecting the top 25 collaborators of Lin Xu. A scholar is included among the top collaborators of Lin Xu based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Lin Xu. Lin Xu is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
#WorkIndexed citations
1 0
2 0
3 16
4 7
5 1
6 1
7 15
8 20
9 25
10
Signaling pathways and targeted therapy for myocardial infarctionbreakdown →
501
11 49
12 3
13 42
14 37
15 5
16 9
17 1
18 2
19 22
20 43

About Lin Xu

Lin Xu is a scholar working on Developmental Neuroscience, Cancer Research and Hepatology, having authored 65 papers that have together received 2.3k indexed citations. Recurring topics across this work include Circular RNAs in diseases (8 papers), Cancer-related molecular mechanisms research (7 papers) and RNA modifications and cancer (6 papers). The work is most often cited by research in Cancer Research (802 citations), Molecular Biology (1.2k citations) and Hepatology (116 citations). Lin Xu has collaborated with scholars based in China, United States and United Kingdom. Frequent co-authors include Kefei Yuan, Mingheng Liao, Chengqi He, Chenying Fu, Quan Wei, Qing Zhang, Hongxin Cheng, Hong Wu, Haotian Liao and Gaiqin Pei. Their work appears in journals such as SHILAP Revista de lepidopterología, PLoS ONE and Cancer Research.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Rankless by CCL
2026